Physician profile
Navin Amin
NPI 1659353308
$1,376.77
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $58.62 · 2021: $98.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $288.14 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $281.41 | 2019 | |
| Eyepoint US, INC. | $173.12 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.58 | 2019 | |
| Sun Pharmaceutical Industries INC. | $160.37 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $124.78 | 2019 | |
| Biotissue Holdings INC. | $105.20 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $22.86 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.98 | 2019 | |
| Shire North American Group INC | $17.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.